ASCEND is a randomised, double blind Phase II study of CEND-1 with standard of care chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).  CEND-1 is a novel agent which aims to improve delivery of chemotherapy treatments through the dense stroma of PDAC.

 

Trial Summary:

To determine the effect of adding CEND-1 to standard of care chemotherapy with gemcitabine and nab‐paclitaxel on progression free survival (PFS)

Supported By:

CEND Therapeutics

Eligibility:

Adults with histologically proven metastatic pancreatic ductal adenocarcinoma suitable for first line gemcitabine and nab‐paclitaxel chemotherapy.

Registration ID:

ACTRN12621001290886

Participation:

Australia, New Zealand

Australian Lead Group:

AGITG

Status:

Recruiting

Activation Date:

13th April 2022

Chairs:

A/Prof Andrew Dean and Prof Tim Price

Contact:

ascend.study@sydney.edu.au